cyrilzakka/clinical-trials huggingface dataset:
Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving

This is a double-blind, crossover trial that will recruit a cohort of non-treatment seeking Cannabis use disordered participants. Participants will then undergo either active, or sham rTMS to the LDLPFC, and cue-induced craving, and risky decision making will be assessed.

Our primary aims are to determine the effect of a single session of 10 Hz L DLPFC rTMS on cannabis cue induced craving (Aim1), and behavioral tasks of impulsive decision making (Aim2), in non-treatment seeking individuals with Cannabis Use Disorder. The aims of the study will be accomplished by performing a double-blind, sham-controlled crossover trial. Non-Treatment seeking individuals with CUD will be recruited through media advertisements, as well as via a pre-established database of non-treatment seeking individuals who have participated in previous Cannabis trials and agreed to be re-contacted. Interested individuals will undergo a brief phone screen to determine if they meet general inclusion/exclusion criteria, and if so will be invited to meet with study personnel in order to sign informed consent, and undergo a screening visit. There will then be two experimental visits separated by at least one week. During each of these visits participants will undergo either a real, or sham rTMS treatment, as well as a cannabis cue Paradigm. Data on craving as well as on impulsive decision making will be collected before and after each treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
2. Participants must be between the ages of 18 and 60.
3. Participants must meet DSM-V criteria for Cannabis Use Disorder, with use of at least 20 days/month.
4. Participants must agree to abstinence from Cannabis for at least 24 hours prior to each visit.
5. Participants must have a Positive UDS for cannabis (confirming they are regular users), and a negative salivary cannabis test (Confirming no use within 10-14 hours)

Exclusion Criteria:

1. Participants must not be pregnant and participate in the study.
2. Participants must not test positive for any substance other than cannabis on UDS.
3. Participants must not meet criteria for any other Substance Use Disorders with the exception of Nicotine Use Disorder.
4. Participants must not be on any medications that have central nervous system effects.
5. Participants Must not have a history of/or current Psychotic disorder.
6. Participants must not have a history of Dementia or other cognitive impairment.
7. Participants must not have active suicidal ideation, or suicide attempt within the past 90 days.
8. Participants must not have any contraindications to receiving rTMS as assessed by the TMS safety sheet.
9. Participants must not have any unstable general medical conditions.
Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis

Prospective, Interventional, Non-Randomized, Open Label, Single Group Assignment, Single Center.


Eligibility Criteria:
Inclusion Criteria:

* 55 to 79 years of age
* Symptomatic Knee osteoarthritis
* VAS pain intensity is at least 40 mm on a 100 mm scale
* Must be physically and mentally willing and able to comply with post-operative rehabilitation and routinely schedule clinical and radiographic visits.

Exclusion Criteria:

* Any known tumor of the ipsilateral knee.
* Any known infection of the treated knee.
* Osteoarthritis of the operated knee Kelgren Lawrence \< grade 2.
* Chemotherapy treatment in the past 12 months.
* Patients who are sensitive to ozone.
* Pregnant women, or breastfeeding women.
* Evidence of any significant systemic disease (such as but not limited to HIV infection, hepatitis infection or HTLV infection), known coagulopathies, that might compromise the Subject's welfare.
* Substance abuse or alcohol abuse.
* Participation in other clinical trials in parallel to this study.
BE@Work: Brief Exercise at Work

BE@Work (Brief Exercise at Work) is a pilot controlled before and after trial of a workplace physical activity programme.

The aim of this study is to investigate the effect of an 8 week workplace physical activity programme on various markers of physical fitness, cardiometabolic health and wellbeing of employees. The primary outcome measures are the following: aerobic fitness, grip strength, leg extensor power, blood pressure, fasting blood glucose levels, lipid profiles, body mass index, waist and hip circumference and self-report measures of psychological wellbeing. The secondary outcome measure is total physical activity. The primary and secondary outcomes measures will be assessed in the control and intervention groups at baseline and at the end of the intervention (8 weeks).

Eligibility Criteria:
Inclusion Criteria:

* Participants will be adult (≥18 years) with no health conditions that preclude them from exercise (information obtained via their self-report) and able to understand written and spoken English. Participants will be cleared for exercise participation via the Physical Activity Readiness Questionnaire Plus (PARQ+)

Exclusion Criteria:

* Exclusion criteria are: Individuals who are not cleared for exercise participation via the PARQ+ will not be eligible to participate. Additionally those unable or unwilling to give informed consent, have any diagnosis or symptoms of cardiovascular or metabolic disease (such as history of heart attack, stroke or diabetes), have been advised by a health professional to avoid physical exercise or activity, are pregnant or might be pregnant and cannot understand and speak English will not be eligible to participate.
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK profiles from a single use of a conventional cigarette (CC) and from a single use of nicotine nasal spray (NNS).


Eligibility Criteria:
Inclusion Criteria:

* Subject is Caucasian
* Smoking, healthy subject as judged by the Investigator.
* Subject has smoked at least 10 commercially available non menthol CCs per day (no brand restrictions) for the last 4 weeks.
* Subject has smoked for at least the last 3 consecutive years.
* Subject does not plan to quit smoking in the next 3 months.

Exclusion Criteria:

* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).
* Subject has received medication within 14 days or within 5 half-lives of a drug (whichever is longer) which has an impact on CYP2A6 activity.
* Female subject is pregnant or breast feeding.
* Female subject does not agree to use an acceptable method of effective contraception.
Effect of Eyelid Patching After Ptosis Surgery

The goal of this randomized, controlled, observer-blinded study is to compare the effect of compression dressing after ptosis surgery.

The main question it aims to answer are:

Effect of dressing on edema, hematoma, scar formation, ocular surface irritation and postoperative pain.

Patients are randomized after surgery for compression dressing or not. Results are scored by a blinded observer.

type of study: clinical trial


Eligibility Criteria:
Inclusion Criteria:

* Ptosis

Exclusion Criteria:

* kongenital ptosis, pre-surgery, trauma
Observational Study on Patients With Hepatocellular Carcinoma (HCC)

This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of HCC;
* Age ≥ 16 years;
* Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
* Good compliance with clinical treatment.

Exclusion Criteria:

* Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;
* Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
* HCC diagnosed after liver transplantation;
* Poor compliance or important data deficient.
177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to determine the safety and efficacy of 177 Lu -labeled PSMA ligand(PSMA-I＆T) in the treatment of mCRPC in Asianethics.

Prostate specific membrane antigen(PSMA) targeted therapy brings new hope to the patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we reported the safety and efficacy of 177 Lu -labeled PSMA ligand(PSMA-I＆T) in the treatment of mCRPC in Asianethics.

Prostate cancer is the most common cancer diagnosed in older men with recent data .PSMA is a type II transmembrane glycoprotein，overexpressed up to 100 to 1000 times higher than normal prostate cells in prostate cancer cells and is correlated with higher-grade cancers, metastatic disease and hormone refractory disease. Lutetium-177 (177Lu)-PSMA (LuPSMA) is a novel and highly targeted systemic RLT for progressive mCRPC. Upon binding of LuPSMA to the cell membrane, endocytosis is triggered, concentrating the tumouricidal effects of the radioisotope activity internally within malignant cells.

This is a single-institution, single-arm phase 2 clinical trial. Patients will receive PRLT Treatment. The follow-up period was followed up to assess safety and effectiveness.

Eligibility Criteria:
Entry criteria

1. ECOG score: 0-1 point
2. Lymph and skeletal metastases or visceral metastases that cannot be removed surgically
3. The disease continues to progress after treatment with ADT, chemotherapy, radiotherapy, or abiraterone and emzaludine 4.68Ga PSMA-11 PET / CT showed that there was significant radioactivity uptake in tumor tissues and metastases \[SUVmax\> 7\], which was significantly higher than that in the liver.

Exclusion criteria

1. Previous treatment with any of the following within 6 months of randomization:

   Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.
2. Hemoglobin\<80g/L;Hemameba\<2.5×109/L;Thrombocyte\<70g/L
3. Glomerular filtration rate\<50ml/min
4. Serum creatinine\>130umol/L;Total bilirubin\>2mg/L;Albumin\<30g/L.
5. International normalized ratio（INR）\>1,5
6. Alanine aminotransferase, aspartate aminotransferase is 5 times larger than normal value
PET/CT Imaging of Aneurysm Wall Inflammation

Rationale: Aneurysm development, progression and rupture are characterised by extensive inflammation, dominated by the infiltration of T-cells, B-cells and macrophages. Recent studies into the pathophysiology of aneurysm wall degradation suggest a close relation between increased mechanical stress and the local activation of infiltrated lymphocytes and macrophages. The non-invasive detection of aneurysm wall inflammation, using 18-fluorodeoxyglucose positron emission tomography (FDG-PET) might therefore provide valuable information on the extend of the disease and could clarify the role of mechanical stress on the propagation of aneurysm wall inflammation.

Objective: Correlation of FDG uptake and in vitro aneurysm wall tensile strength. (primary objective). The effect of aneurysm sac depressurisation, after endovascular aneurysm repair, on aneurysm wall inflammation (secondary objective).

Study design: Observational case series (pilot). Study population: Patients scheduled for conventional (open) and endovascular aneurysm repair.

Main study parameters: Standard uptake value (SUV) measurements to asses FDG uptake in the aneurysm wall and in vitro aneurysm wall strength (N/mm).

Nature and extent of the burden and risks associated with participation,

benefit and group relatedness: Patients scheduled for conventional (open) or endovascular aneurysm repair are admitted to the hospital the day before surgery. At that point all patients will be evaluated using FDG-PET. Although intake of sugar-free liquids is permitted, glucose intake is restricted 6 hours prior to FDG-PET imaging. One hour after intravenous injection of 200-220 MBq FDG, whole body emission and transmission images will be acquired. To determine inflammation markers ( e.g. CRP), blood and urine samples will be collected prior to the operation and again 6 weeks after surgery. For in vitro aneurysm wall tensile strength testing wall specimens will be harvested during conventional aneurysm repair.


Eligibility Criteria:
Inclusion Criteria:

* scheduled for conventional (10 patients) or endovascular (25 patients) aneurysm repair.
* Informed consent

Exclusion Criteria:

* Diabetes Mellitus type 1 en 2
Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Stress Urinary Incontinence

Randomized comparison of two surgeries for the treatment of female stress urinary incontinence.


Eligibility Criteria:
Inclusion Criteria:

* women with stress urinary incontinence with a positive cough test
* patient request surgery for treatment

Exclusion Criteria:

* prodominantely overactive bladder
* previous failed procedure
* MUCP \<20 cm H2O
* presence of vaginal prolapse \> stage 1
* voiding dysfunction (PVR\>100 mL)
Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in Vitiligo

A randomized controlled non-inferiority trial based on split-body was planned to compare the efficacy of 308-nm excimer laser and 311-nm Ti:Sapphire laser in patients with vitiligo.

The 308-nm excimer laser (EL) has been widely used for localized vitiligo. Recently, the 311-nm Ti:Sapphire laser (TSL) was developed to treat patients with vitiligo. To compare the efficacy of TSL vs. EL in the treatment of vitiligo.

A randomized controlled non-inferiority trial based on split-body was planned. The paired symmetric vitiliginous lesions will be randomized to either TSL or EL treatment groups. All lesions will be treated twice weekly for a total of 12-week period. The degree of repigmentation will be assessed as % from baseline by using a computer program every 4 weeks, and the non-inferiority margin was set at 10%. Overall 16 patients will be enrolled.

Eligibility Criteria:
Inclusion Criteria:

* Age: older than 19
* A patient with stable non-segmental vitiligo
* A patient with symmetrical vitiligo lesions
* A patient with the willingness to comply with the study protocol during the study period and capable of complying with it
* A patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages

Exclusion Criteria:

* Age: lower than 20
* A pregnant or lactating patient
* A patient with active or spreading vitiligo
* A patient who cannot understand the study or who does not sign the informed consent
Describe the Effect of the Optimized Hemodialysis Technique (HDx) With Medium Cut-Off Membrane on Recovery Time and Quality of Life

In this study, the effect of optimizing the dialytic technique using simple questionnaires carried out in clinical routine will be described.

More specifically, the conventional dialysis technique will be combined with biofeedback software called HemoControl™. The recovery time and quality of life of patients who will use a polyethersulfone membrane (Revaclear®) and a Medium Cut-Off (MCO) membrane (Theranova®) will be observed.

The main objective is to describe the evolution of recovery time after a dialysis session in conventional hemodialysis (HD) on Revaclear® membrane and in so-called optimized hemodialysis (HDx) on MCO membrane, Theranova®.


Eligibility Criteria:
Inclusion Criteria:

* Patient, male or female (using contraceptives, if of childbearing age), over 18 years of age
* Patient on conventional hemodialysis with synthetic membrane for at least 3 months
* Patient with a recovery time after the dialysis session ≥ 4 hours
* Informed patient who has signed a written consent to participate in the study
* Affiliated patient or beneficiary of a social security scheme

Exclusion Criteria:

* Patient whose seniority of dialysis is less than 3 months
* Pregnant woman
* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
* Patient with severe cognitive impairment
* Medically unstable or frail patient
* Patient who did not sign an informed consent form accepting this research (refusal of consent or absence of signature).
Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem

This is a retrospective/prospective study evaluating the clinical and radiographic outcome of total hip arthroplasty (THA) performed using Accolade femoral stem in a consecutive group of patients. All patients eligible for inclusion will be identified. The investigators hypothesize that the outcome of THA performed using Accolade femoral stem is equal or superior to historical survivorship of THA using other types of collarless, proximally coated, tapered stems.


Eligibility Criteria:
Inclusion Criteria:

1. All patients undergoing THA prior to 1/1/2003 using Accolade femoral stem.
2. Patients with hip fracture undergoing THA will also be included.
3. Patients willing and able to comply with follow-up requirements and self-evaluations.
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients

The purpose of this study is to define an improvement in patients:

* To evaluate if patients resistant to the initial treatment for residual PET-positive masses after the first two courses of ABVD (PET-2 positive), can be salvaged by early shift to high-dose chemotherapy supported by stem cell rescue
* To analyse if patients achieving early complete response (PET-2 negative), can be spared the adjuvant radiotherapy on areas of initial bulky disease, at the end of the planned six courses of ABVD. To answer this question, PET-2 negative patients will be randomized between radiotherapy versus no radiotherapy at the end of ABVD therapy.

This study is composed by two phases:

1. A phase II multi-centre study evaluating in patients with advanced stage Hodgkin lymphoma the efficacy of an early salvage treatment with high-dose chemotherapy followed by stem cell transplantation in patients FDG-PET positive after two courses of ABVD (PET-2 positive).
2. A phase III randomised study comparing the efficacy of radiotherapy to the areas of initial bulky disease versus no further therapy in PET-2 negative patients in complete remission (PET-6 negative) at the end of six courses of ABVD.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed Hodgkin's lymphoma of the classical type (nodular lymphocyte predominance excluded).
* Stage IIB-IV.
* Age 18-70.
* No prior therapy for Hodgkin's lymphoma
* Written informed consent.
* ECOG performance status grades 0-3 (see Appendix E).
* FDG-PET scan before the initiation of treatment.

Exclusion Criteria:

* Prior therapy for Hodgkin's lymphoma.
* Age less than 18 or more than 70.
* Other concomitant or prior malignancies, except basal cell skin carcinoma, or adequately treated carcinoma in situ of the cervix, or any cancer in complete remission for more than 5 years.
* HIV infection.
* Pregnancy or breast-feeding.
* Renal failure (creatinine ≥2 times the normal value), liver failure (AST/ALT or bilirubine ≥ 2.5 times the normal value) or heart failure (NYHA class ≥ 2 or FEV \< 45%).
Therasphere for Unresectable Primary or Secondary Liver Neoplasia

This is not a research study. The purpose is to provide supervised access to TheraSphere® therapy at this institution.


Eligibility Criteria:
Inclusion Criteria:

* Patients will be recruited from the patient population referred to the principal clinician for regional liver cancer therapy.
* Potential candidates are those diagnosed with primary or secondary liver neoplasia. The histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers and clinical findings. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) describe in detail the approach and algorithm for diagnosing Hepatocellular Carcinoma (HCC).
* Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0 - 2
* Life expectancy ≥ 3 months
* \> 4 weeks since prior radiation, surgery or chemotherapy
* Able to comprehend and provide consent in accordance with institutional and federal guidelines

Exclusion Criteria:

* Any other liver therapy planned for cancer treatment
* Uncorrectable flow to the gastrointestinal tract
* Estimated radiation doses to the lungs greater than 30 Gy in a single administration or 50 Gy in multiple administrations
* Significant extrahepatic disease representing imminent life-threatening outcome
* Pregnancy
Ovarian Functions in Flight Attendants

The aim of this study was to evaluate the effects of night sleep disorder and sleeplessness, excessive hours spent on flight and UV radiation exposure over ovarian function in flight attendant women.

The aim of this study was to evaluate the effects of night sleep disorder and sleeplessness, excessive hours spent on flight and UV radiation exposure over ovarian function in flight attendant women.

On the third day of the menstrual period, evaluate the number of antral follicle count will be examined and the level of hormones showing the ovarian functions will be measured in the blood sample given by the participant.

Eligibility Criteria:
Inclusion Criteria:

* day working women , 25-35 years old
* night working women , 25-35 years old
* flight attendant women, 25-35 years old

Exclusion Criteria:

* those who cannot enter the groups above